We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Alexander Beadle

Science Writer

Contact Us

Alexander Beadle has been working as a freelance science writer since 2017 and has covered the cannabis industry for Analytical Cannabis since 2018. He has also written for our sister publication, Technology Networks, and the cannabis industry consultant firm Prohibition Partners, among others. Alexander holds an MChem in materials chemistry from the University of St Andrews, where he won a Chemistry Purdie Scholarship and conducted research into zeolite crystal growth mechanisms and the action of single-molecule transistors.

Latest Content From Alexander Beadle

Psilocybin Can Enhance How People Emotionally Connect to Music

Taking psilocybin can affect one’s emotional state when listening to music, according to new research presented earlier this month.

VIEW

State Cannabis Policies Significantly Impacted the Scale of their EVALI Outbreak, Study Finds

States with legal recreational cannabis markets were less likely to report large numbers of ​​e-cigarette or vaping-associated lung injury (EVALI) cases during the 2019 vaping crisis, a new study has found.

VIEW

Can Ketamine Relieve Injury Pain?

To address this, two British ambulance services are now participating in a new trial to investigate whether ketamine injections may be a more effective relief treatment for severe injury pain than the current treatment options available to Britain’s first responders.

VIEW

Three Rare Cannabinoids May Help to Stop Seizures, Study Suggests

The study, which was published in the British Journal of Pharmacology, found that CBGA was the most potent of the three and may also affect many of the same therapeutic targets that are targeted by traditional anti-epilepsy drugs.

VIEW

Cannabis Consumers at Higher Risk of Developing Poor Mental Health, Study Suggests

People with a history of cannabis use in their medical records appear to be at a higher risk for developing problems with anxiety, depression, and even more severe mental illnesses such as schizophrenia, according to a new study from researchers at the University of Birmingham.

VIEW

Can Psilocybin Help Smokers Quit? This Clinical Trial Aims to Find Out

Mydecine Innovations Group has announced its partnership with the renowned psychedelic science researcher Dr Matthew Johnson of Johns Hopkins University to carry the clinical trial.

VIEW

Could Ketamine Help Tackle Gambling Addiction?

Recruitment is now underway for a first-of-its-kind study investigating the potential of ketamine to fight gambling addiction.

VIEW

Ketamine Alone May Effectively Treat Depression, Study Suggests

Ketamine alone may be just as effective as ketamine combined with traditional antidepressants for tackling treatment-resistant depression, a new study has found.

VIEW

Analyzing an Extended Terpenes List in a Commercial Cannabis Laboratory

Think20 Laboratories’ commercial operations manager Adam Floyd explains how extended terpene analysis is done in a commercial cannabis laboratory and details the considerations needed when building a suitable analytical method for terpene analysis.

VIEW

CBD Enhances Episodic Memory, Study Finds

The researchers believe that these findings demonstrate a potential therapeutic application for CBD in tackling episodic memory deficits in disorders such as Alzheimer’s disease or schizophrenia.

VIEW